Literature DB >> 17100109

Viral hepatitis in India.

S K Acharya1, Kaushal Madan, S Dattagupta, S K Panda.   

Abstract

Viral hepatitis is a major public health problem in India, which is hyperendemic for HAV and HEV. Seroprevalence studies reveal that 90%-100% of the population acquires anti-HAV antibody and becomes immune by adolescence. Many epidemics of HEV have been reported from India. HAV related liver disease is uncommon in India and occurs mainly in children. HEV is also the major cause of sporadic adult acute viral hepatitis and ALF. Pregnant women and patients with CLD constitute the high risk groups to contract HEV infection, and HEV-induced mortality among them is substantial, which underlines the need for preventive measures for such groups. Children with HAV and HEV coinfection are prone to develop ALF. India has intermediate HBV endemicity, with a carrier frequency of 2%-4%. HBV is the major cause of CLD and HCC. Chronic HBV infection in India is acquired in childhood, presumably before 5 years of age, through horizontal transmission. Vertical transmission of HBV in India is considered to be infrequent. Inclusion of HBV vaccination in the expanded programme of immunization is essential to reduce the HBV carrier frequency and disease burden. HBV genotypes A and D are prevalent in India, which are similar to the HBV genotypes in the West. HCV infection in India has a population prevalence of around 1%, and occurs predominantly through transfusion and the use of unsterile glass syringes. HCV genotypes 3 and 2 are prevalent in 60%-80% of the population and they respond well to a combination of interferon and ribavirin. About 10%-15% of CLD and HCC are associated with HCV infection in India. HCV infection is also a major cause of post-transfusion hepatitis. HDV infection is infrequent in India and is present about 5%-10% of patients with HBV-related liver disease. HCC appears to be less common in India than would be expected from the prevalence rates of HBV and HCV. The high disease burden of viral hepatitis and related CLD in India, calls for the setting up of a hepatitis registry and formulation of government-supported prevention and control strategies.

Entities:  

Mesh:

Year:  2006        PMID: 17100109

Source DB:  PubMed          Journal:  Natl Med J India        ISSN: 0970-258X            Impact factor:   0.537


  48 in total

1.  Hepatitis E: are psychiatric patients on special risk?

Authors:  Claudia Reinheimer; Regina Allwinn; Annemarie Berger
Journal:  Med Microbiol Immunol       Date:  2011-10-18       Impact factor: 3.402

2.  Genotype 1 hepatitis C virus infection predominates among patients with chronic kidney failure and renal allograft recipients in India.

Authors:  Avnish Kumar Seth; Alok Chandra; Pankaj Puri; Jasmeet Kaur
Journal:  Indian J Gastroenterol       Date:  2009 Jul-Aug

3.  Hepatitis B virus subgenotype A1 predominates in liver disease patients from Kerala, India.

Authors:  Deepak Gopalakrishnan; Mark Keyter; Kotacherry Trivikrama Shenoy; Kondarappassery Balakumaran Leena; Lakshmikanthan Thayumanavan; Varghese Thomas; Kr Vinayakumar; Charles Panackel; Arun T Korah; Ramesh Nair; Anna Kramvis
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

4.  Hepatitis C, a silent threat to the community of Haryana, India: a community-based study.

Authors:  Ramesh Verma; Binod Kumar Behera; R B Jain; Varun Arora; Vinod Chayal; P S Gill
Journal:  Australas Med J       Date:  2014-01-31

5.  Prevalence of HBV and HCV in blood donors in Kanpur during the period 1997 through 2005.

Authors:  Riddhi Jaiswal; Lubna Khan; Renu Jain; Asha Agarwal; S N Singh
Journal:  Indian J Hematol Blood Transfus       Date:  2008-03-19       Impact factor: 0.900

6.  Hepatitis C in Punjab--peeping into Pandora's box!

Authors:  Sk Mahiuddin Ahammed; Abhijit Chowdhury
Journal:  Indian J Gastroenterol       Date:  2012-10-20

Review 7.  Role of surveillance in prevention of hepatocellular carcinoma.

Authors:  Dipanjan Panda
Journal:  J Clin Exp Hepatol       Date:  2014-05-25

8.  Identifying and describing a cohort effect in the national database of reported cases of hepatitis C virus infection in Canada (1991-2010): an age-period-cohort analysis.

Authors:  Max Trubnikov; Ping Yan; Jane Njihia; Chris Archibald
Journal:  CMAJ Open       Date:  2014-10-01

9.  Hepatitis B virus genotyping: is the time ripe for routine clinical use?

Authors:  Kaushal Madan; Pankaj Tyagi
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

10.  Problem drug use the public health imperative: what some of the literature says.

Authors:  Gez Bevan
Journal:  Subst Abuse Treat Prev Policy       Date:  2009-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.